|

ONO-4538 Phase II Rollover Study (ONO-4538-98)

RECRUITINGPhase 2Sponsored by Ono Pharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorOno Pharmaceutical Co., Ltd.
Started2020-09-10
Est. completion2026-12-31
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04566380

Summary

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

Eligibility

Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit

Exclusion Criteria:

1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia
2. Participant judged by the investigator to be inappropriate as participants of this study

Conditions2

CancerPan-tumor

Interventions6

BevacizumabCapecitabineONO-4538OxaliplatinS-1Temozolomide

Related trials

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.